SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bellomio, V
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellomio, V
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Correction for Lupus 0 (2009) 0961203309358481v1.

research-article

Metabolic syndrome in Argentinean patients with systemic lupus erythematosus

V Bellomio

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentinavbellomio{at}arnet.com.ar

A Spindler

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

E Lucero

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

A Berman

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

R Sueldo

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

H Berman

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

M Santana

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

MJ Molina

Servicio de Reumatología, Hospital Angel Padilla, Universidad Nacional de Tucumán, Tucumán, Argentina

V Góngora

Hospital J .M. Cullen, Santa Fé, Argentina

G Cassano

Hospital J .M. Cullen, Santa Fé, Argentina

S Paira

Hospital J .M. Cullen, Santa Fé, Argentina

V Saurit

Hospital Privado de Córdoba, Córdoba, Argentina

G Retamozo

Hospital Privado de Córdoba, Córdoba, Argentina

A Alvarellos

Hospital Privado de Córdoba, Córdoba, Argentina

F Caerio

Hospital Privado de Córdoba, Córdoba, Argentina

P Alba

Hospital Córdoba, Córdoba, Argentina

M Gotero

Hospital Córdoba, Córdoba, Argentina

EJ Velozo

Hospital Italiano, Buenos Aires, Argentina

F Ceballos

Hospital Italiano, Buenos Aires, Argentina

E Soriano

Hospital Italiano, Buenos Aires, Argentina

L Catoggio

Hospital Italiano, Buenos Aires, Argentina

MA García

Hospital General San Martín, La Plata, Argentina

A Eimon

CEMIC, Buenos Aires, Argentina

S Agüero

Sanatorio Pasteur, Catamarca, Argentina

SLE Study Group of the Argentinean Society of Rheumatology

The objective was to determine the prevalence of the metabolic syndrome (MS) in patients with systemic lupus erythematosus (SLE) in Argentina, to assess the factors associated to it, and to compare the results with a control group with non-inflammatory disorders. The study included 147 patients with SLE and 119 controls. MS was defined according to criteria by the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) Scientific Statement. Demographic characteristics, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) were assessed as well as administration, maximum dose and cumulative dose of prednisone and hydroxychloroquine (HCQ). MS prevalence was 28.6% (CI 95%: 21.4–36.6) in patients with SLE and 16% in controls (P = 0.0019). Patients with SLE presented higher arterial hypertension frequency compared with controls (43 vs 25%, P = 0.007). When comparing lupus patients with MS (n = 41) and without MS (n = 106), no significant differences were observed regarding duration of the disease, SLEDAI or cumulative prednisone dose. Cumulative damage was associated independently with MS (OR 1.98; P = 0.021), whereas HCQ use was found to be protective (OR 0.13; P = 0.015). Patients with lupus presented higher MS prevalence than controls with non-inflammatory disorders, and occurrence of arterial hypertension was also higher. MS was associated with cumulative damage; the use of HCQ showed to be protective against presence of MS.

Key Words: metabolic syndrome • systemic lupus erythematosus

Lupus, Vol. 18, No. 11, 1019-1025 (2009)
DOI: 10.1177/0961203309105876
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement